Jun Gong, MD (@jgong15) ranks #6 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 25 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: RASolute 302, HERIZON-GEA-01, CRITICS-II. CMS Open Payments lists $53,340 in 2025 general payments.
At a Glance
- 20 posts naming a trial in 2026
- 15 trials discussed by name
- GI Cancer: US #6, Global #19 · 25 physicians engaged
- Leading physician voice: #1 of 3 physicians on LITESPARK-024; #1 of 3 physicians on DISCO
- CMS Open Payments lists $53,340 in 2025 general payments.
This Month
What Jun Gong, MD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Jun Gong, MD
Physicians who reposted Jun Gong, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GI Cancer | #6 | #19 | 25 | 48 | Full ranking |
What Colleagues Are Saying About Jun Gong, MD
2026 posts by fellow physicians that mention @jgong15, quoted word for word.
Agree with @jgong15. Good to see studies and investigators doing the right thing and reevaluating continuation of studies when new data becomes available and standards of care changes. Putting patients first is key. @ASCO #GI26 https://t.co/LYoWqqsKrR
Another year of @binaytara conference in Fresno, CA, with @jgong15 ! Dr. Jun Gong provided an update of new approvals and landmark studies in #colorectalcancer This year, we have BREAKWATER update, STELLAR-303, CHALLENGE update, ATOMIC, COMMIT, and many more! @DaniCastilloMD @binayshah
Trials Jun Gong, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| RASolute 302 | 3 | #15 of 73 | Aug 27, 2026 |
| HERIZON-GEA-01 | 3 | #17 of 34 | Aug 23, 2026 |
| CRITICS-II | 2 | #5 of 7 | Jan 8, 2026 |
| HARMONi-6 | 1 | #21 of 74 | May 31, 2026 |
| TALAPRO-3 | 1 | #32 of 39 | May 30, 2026 |
| ARACOG | 1 | #9 of 10 | May 30, 2026 |
| EV-302 | 1 | #14 of 19 | May 29, 2026 |
| LITESPARK-024 | 1 | #1 of 3 | Feb 28, 2026 |
| COMMIT | 1 | #8 of 14 | Jan 10, 2026 |
| DISCO | 1 | #1 of 3 | Jan 10, 2026 |
| COLOCARE | 1 | — | Jan 10, 2026 |
| ALTOPANC | 1 | — | Jan 10, 2026 |
| BREAKWATER | 1 | #17 of 22 | Jan 10, 2026 |
| LYRICX | 1 | — | Jan 9, 2026 |
| ILUSTRO | 1 | #5 of 11 | Jan 8, 2026 |
Jun Gong, MD on RASolute 302
#1L trials in #mPDAC are vital. Assuming control arms will be chemo pending #1L chemo + RASi data, learning from RASolute 302 ➡️ 55/214 (26%) pts withdrew/deteriorated upon tx in ctrl arm, also an add’l 38 pt dropout on rand to ctrl arm 🟰high future attrition rates❓@OncoAlert https://t.co/KJgFNH2gtd
Dr. Knox @UHN discussant on RASolute 302, no one should have limited access to #daraxonrasib, noting 29 pts withdrew if randomized to unblinded IC chemo arm. FDA should expedite, can we really do @US_FDA early access for everyone?? #ASCO26 @OncoAlert @guildsman @IbrahimSahinMD1 https://t.co/dzzOYoNvNo
Dr. Wolpin PhIII RASolute 302 trial of #2L #daraxonrasib (RAS(ON) inh) vs IC chemo in met #PDAC ➡️ median OS 13.2 vs 6.6 mos (HR 0.40❗️) , mPFS 7.3 vs 3.5 mos, ORR 33.2% vs 11.8%, 1.2% discont rate for daraxonrasib (rash, stomatitis most commonly led to DR) #ASCO26 @OncoAlert https://t.co/PmiBXxr4D5
Jun Gong, MD on HERIZON-GEA-01
@ronanhsieh w/a masterful discussion of upper #GI cancer updates including a breakdown of HERIZON-GEA-01 & its implications once approved @binaytara conference @fresnohotel we separately went to @YosemiteNPS after to digest these high-impact studies 😊 @DaniCastilloMD @OncoAlert https://t.co/PMid4UMzQJ https://t.co/m5xhpn9F4H
@DanielLinMD @KimmelCancerCtr @TJUHospital insightful discussion of Dr. Elimova HERIZON-GEA-01 presentation, citing notable pros/cons. Of note, zani + chemo OS comparison with lots of alpha left in immature analysis @OncoAlert #GI26 https://t.co/fUQHtdk0Cf
Dr. Elinor’s rand PhIII HERIZON-GEA-01 #1L #HER2+ adv #GC/GEJ/EAC ➡️ zani-containing regimens >4 mos prolongation of median PFS vs trastuzumab + CT, > 7 mos improvement in OS w/triplet of zani + CT + tisle vs control arm. Diarrhea manageable with prophylaxis @OncoAlert #GI26 https://t.co/S75KsnVWB6
Jun Gong, MD on CRITICS-II
Dr. Hallemeier excellent discussion on CRITICS-II vs TOPGEAR, noting differences in absence of IO & periop vs TNT approaches between studies including study heterogeneity. Important for further study & great slide on scenarios where neoadj CRT may have a role @OncoAlert #GI26 https://t.co/sBbnbIVhG4
Dr. Verheij CRITICS-II rand PhII pick-the-winner neoadj tx strategies in resectable #GC/GEJC ➡️ total neoadjuvant chemo + chemoRT w/best outcomes & preferred candidate for further study, notably no adjuvant tx but addition of CRT to #chemoIO new avenue of study? @OncoAlert #GI26 https://t.co/VvfsOJejtE
Jun Gong, MD on HARMONi-6
Positive PhIII HARMONi-6 trial #ASCO26 @OncoAlert in adv squamous #NSCLC provides momentum for @SMMT_TX HARMONI-Gi3 PhIII trial of #1L ivonescimab (anti-PD-1/VEGF) or bev + FOLFOX in patients with #mCRC, for which we are a participating site @CedarsSinai https://t.co/xuHXfLbL6U https://t.co/Rhuqtrz8o9
Jun Gong, MD on TALAPRO-3
@neerajaiims PhIII TALAPRO-3 of #ADT + enza +/- talazoparib in #1L HRR-mutant #mCSPC ➡️ improved rPFS in BRCA/non-BRCA-mt pts in tala arm, OS immature, G3-4 TRAEs 79% vs 41% in control, 3 cases MDS & 2 cases AML (tala arm) vs 1 case MDS/AML (control arm) #ASCO26 @OncoAlert https://t.co/BVeSMGuncy
Jun Gong, MD on ARACOG
@CaPsurvivorship PhII #ARACOG of darolutamide vs enza in adv #pcsm (50-55% mHSPC) ➡️ greater decline in maximally changed cognitive domain (mainly in working memory and executive function) w/enza than daro over 24 weeks, enza offered by #SOC, daro by sponsor #ASCO26 @OncoAlert https://t.co/O2RWd5q5Jc
Jun Gong, MD on EV-302
@tompowles1 EV-302 of #1L EV-P vs platinum-chemo in #mUC ➡️ updated OS at 3.5 yrs 44% vs 24.6% alive, median 4.3 mos to #CR w/even pts up to 1 yr converting from #PR to #CR, 10% achieve #CR at first scan w/EV-P, (median duration of EV 7.1 mos & 8.5 mos pembro) #ASCO26 @OncoAlert https://t.co/5COrRmmxqP
Jun Gong, MD on LITESPARK-024
Dr. McDermott @BIDMChealth PhI/II LITESPARK-024 trial of belzutifan + palbociclib in adv #ccRCC (>2 prior lines) ➡️ at MTD 125 mg palbo, ORR 21.1%, median PFS 9.1 mos, most common G>3 AE being neutropenia @OncoAlert #GU26 https://t.co/4IvjhWsaEu
Jun Gong, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Dr. Galle 4-year follow-up of CM9DW of #1L nivo/ipi vs. len/sorafenib in adv #HCC ➡️ sustained OS benefit median 23.7 vs 20.6 mos, ORR 36% (8% CR) vs 13% (2% CR) in favor of nivo/ipi. 4% G5 AEs with nivo/ipi vs <1% control arm @OncoAlert #GI26 https://t.co/ZxOdmAA8XY
Dr. Chan @CUHKofficial rand PhIII KN-937 trial of adj #pembrolizumab X1 year in #HCC after surgery or local ablation ➡️ no sig improvement in #RFS (primary endpoint) vs placebo (HR 1.06), no diff in OS or met-free survival. Follows negative IMbrave050 trial @OncoAlert #GI26 https://t.co/fTm1RpkNFE
Dr. Wainberg PhI single-arm INCB161734, novel selective ON/OFF oral #KRASG12D inh, in #KRASG12D mut met PDAC (median 2 prior lines in monotherapy cohort ) ➡️ ORR 37% mono ORR 50% w/#GA or #mFFX (median 1 prior lines in chemo arms). ⬆️ KRAS CN ?resistance mech @OncoAlert #GI26 https://t.co/s9RKIi3uyA
Dr. Halle PhIII rand IKF-035/ABC-CC of atezo/bev vs #TACE in intermediate-stage #HCC not amenable to surgery, transplant or ablation ➡️ interim improved time to failure of treatment strategy (TTFS) 14.6 mos vs 9.5 mos in favor of atezo/bev over #TACE @OncoAlert #GI26 https://t.co/3JOrLNSqt1
This one flew under the radar with all the RAS(ON) inh #daraxonrasib coverage at #AACR26: induction of MSI-H w/CRs to #ICI in preclinical cancer models testing first-in-class #PMS2 inhibitor https://t.co/vy0v5TDvA9 @OncoAlert @AACR @CD_AACR @RenoHemonc @manjuggm @ElizSMcKenna https://t.co/C9JW5y4nBb
Industry Payments
CMS Open Payments · 2025 general payments
$53,340 across 44 payments